Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers opinion on when sipuleucel-T should be used in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers opinion on when sipuleucel-T should be used in the treatment ...

Tian Zhang, MD, on whether patients in the 1st line setting should receive a single agent TKI

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, offers opinion on whether patients in the first line setting should receive a single agent TKI

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, offers opinion on whether patients in the first line setting should ...

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on combining checkpoint inhibitors with PARP inhibitors, chemotherapy, and anti-hormone agents in metastatic castration-resistant prostate cancer (mCRPC)

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on combining checkpoint inhibitors with PARP inhibitors, chemotherapy, and anti-hormone ...

Michael Atkins, MD, regarding single agent TKIs in the 1st line setting

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, considers whether patients in the first line setting may receive a single agent TKI

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, considers combination pembrolizumab and olaparib and what primary endpoints should look like in these first line metastatic castration-resistant prostate cancer (mCRPC) trials

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, considers combination pembrolizumab and olaparib and what primary endpoints should look ...

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination I-O in the 1st line setting

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination ...

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, tell us about the results of KEYNOTE 365 investigating the use of pembrolizumab combined with olaparib in metastatic castration-resistant prostate cancer (mCRPC)

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, tell us about the results of KEYNOTE 365 investigating the use ...

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, explains how to treat metastatic renal cell carcinoma (mRCC) patients who progress after combination I-O in the first line setting

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on how androgen deprivation therapy (ADT) is changing for men with newly diagnosed metastatic hormone therapy naïve prostate cancer

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on how androgen deprivation therapy (ADT) is changing for men ...

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how we may treat intermediate/poor risk renal cell cancer (RCC) patients versus those that are favorable risk in the first line setting

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how we may treat intermediate/poor risk renal cell cancer ...